Key Highlights
- ALPHA3 trial demonstrated 58.3% MRD negativity in patients receiving cema-cel compared to just 16.7% in the observation group
- Zero cases of cytokine release syndrome or neurotoxicity reported among treated participants
- Baird upgraded ALLO price target from $7.00 to $9.00 while maintaining Outperform rating
- Analysts increased probability of success projection for the therapy to 70%
- Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date
Shares of Allogene Therapeutics experienced a dramatic rally of more than 41% on April 13, 2026, following the disclosure of encouraging interim results from the company’s pivotal Phase 2 ALPHA3 clinical trial. The study is evaluating cemacabtagene ansegedleucel (cema-cel) in patients diagnosed with high-risk large B-cell lymphoma.
Allogene Therapeutics, Inc., ALLO
The disclosed information came from an interim futility analysis conducted during the trial. Results from the initial 24 randomized participants revealed that 58.3% of those receiving cema-cel achieved minimal residual disease (MRD) negativity. By contrast, the observation arm recorded only 16.7% reaching this milestone — representing a notable 41.6 percentage point differential.
The clinical trial employs Natera’s investigational CLARITY MRD assay as a tool for detecting high-risk patients prior to observable clinical relapse. The study positions cema-cel as a first-line consolidation treatment option, potentially advancing its use earlier in the therapeutic sequence compared to existing CAR T methodologies.
Remarkable Safety Results Capture Market Interest
The safety findings generated significant attention, potentially matching the importance of the efficacy outcomes. Remarkably, none of the patients who received treatment developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — complications frequently linked to CAR T therapeutic approaches.
No serious adverse events attributed to treatment were documented. Such a favorable safety profile stands out in the oncology landscape, with Baird analysts highlighting this as a key distinguishing characteristic when evaluating cema-cel against second-line autologous CAR T alternatives.
The potential for outpatient administration, paired with the encouraging safety metrics, positions this program as potentially unique in the field. Current CAR T treatments typically necessitate inpatient care and present more substantial toxicity challenges.
Following the data announcement, Baird elevated its ALLO price target to $9.00 from the previous $7.00 while retaining an Outperform rating. The investment firm also raised its success probability assessment for the therapeutic program to 70%.
“The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.
Future Milestones and Timeline
The ALPHA3 clinical study is currently recruiting approximately 220 participants across more than 60 clinical sites. Efficacy endpoints continue to remain blinded during this phase, and the available dataset remains limited in size. The durability of these initial findings will require validation as additional data becomes available.
Scheduled interim event-free survival analyses are anticipated to arrive in 2027, with complete primary outcome data projected for 2028. Favorable results from these analyses could pave the way for a biologics license application submission.
The company has attracted broader analyst attention beyond Baird. Jefferies recently launched coverage on ALLO with a Buy recommendation and established a $6.00 price objective, while Citizens maintained its Market Outperform stance with a $5.00 target price.
ALLO shares reached $3.87 on April 13, climbing from the previous closing price of $2.91. The stock has appreciated approximately 99% since the beginning of the year and is currently trading near its 52-week peak. According to InvestingPro analysis, the stock is presently valued above its calculated fair value estimate, though the company maintains a balance sheet with greater cash holdings than debt obligations.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
